{"created":"2024-09-26T07:32:38.303635+00:00","id":2020587,"links":{},"metadata":{"_buckets":{"deposit":"3aeb2ff2-7bb5-4fbf-8f13-af71b9341221"},"_deposit":{"created_by":8,"id":"2020587","owner":"8","owners":[8],"pid":{"revision_id":0,"type":"depid","value":"2020587"},"status":"published"},"_oai":{"id":"oai:u-ryukyu.repo.nii.ac.jp:02020587","sets":["1642838163960:1642838338003","1642838403551:1642838407795"]},"author_link":[],"control_number":"2020587","item_1617186331708":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_title":"Effectiveness of Surveillance by Echocardiography for Cancer Therapeutics-Related Cardiac Dysfunction of Patients with Breast Cancer","subitem_title_language":"en"}]},"item_1617186419668":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Okushi, Yuichiro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Saijo, Yoshihito","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Yamada, Hirotsugu","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Toba, Hiroaki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Zheng, Robert","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Seno, Hiromitsu","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Takahashi, Tomonori","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Ise, Takayuki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Yamaguchi, Koji","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Yagi, Shusuke","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Soeki, Takeshi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Wakatsuki, Tetsuzo","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Sata, Masataka","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kusunose, Kenya","creatorNameLang":"en"}]}]},"item_1617186476635":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_1617186499011":{"attribute_name":"Rights","attribute_value_mlt":[{"subitem_rights":"This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) license","subitem_rights_language":"en","subitem_rights_resource":"https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja"}]},"item_1617186609386":{"attribute_name":"Subject","attribute_value_mlt":[{"subitem_subject":"Heart failure","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Cardio oncology","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Cardiotoxic drugs","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Echocardiography surveillance","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_1617186626617":{"attribute_name":"Description","attribute_value_mlt":[{"subitem_description":"Background: Cancer therapeutics-related cardiac dysfunction (CTRCD) affect the prognosis of patients with breast cancer. Echocardiographic surveillance of patients treated with anti-human epidermal growth factor receptor type 2 (HER2) antibodies has been recommended, but few reports have provided evidence on patients with breast cancer only. We aimed to evaluate the effectiveness of echocardiographic surveillance for breast cancer patients. Methods: We identified 250 patients with breast cancer who were treated with anti-HER2 antibodies from July 2007 to September 2021. We divided 48 patients with echocardiographic surveillance every 3 months into the surveillance group and 202 patients without echocardiographic surveillance into the non-surveillance group. In the surveillance group, patients with a considerable reduction in global longitudinal strain of 15% were considered for the initiation of cardioprotective drugs. The composite outcome of CTRCD and acute heart failure was the study endpoint. Results: The mean age was 59 ± 12 years. During the follow-up period of 15 months (12- 17 months), 12 patients reached the endpoint. The surveillance group had significantly lower incidence of the composite outcome (2.1% vs. 5.5%, adjusted odds ratio: 0.28, 95% confidential intervals: 0.09–0.94; p=0.039) and higher rates of prescriptions of cardioprotective drugs than the non-surveillance group. Conclusions: The incidence of cardiac complications was significantly lower in the surveillance group than the non-surveillance group, which supports the effectiveness of echocardiographic surveillance in patients with breast cancer.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_1617186643794":{"attribute_name":"Publisher","attribute_value_mlt":[{"subitem_publisher":"Elsevier","subitem_publisher_language":"en"}]},"item_1617186702042":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_1617186783814":{"attribute_name":"Identifier","attribute_value_mlt":[{"subitem_identifier_type":"DOI","subitem_identifier_uri":"https://doi.org/10.1016/j.jjcc.2023.07.002"}]},"item_1617186920753":{"attribute_name":"Source Identifier","attribute_value_mlt":[{"subitem_source_identifier":"0914-5087","subitem_source_identifier_type":"PISSN"},{"subitem_source_identifier":"1876-4738","subitem_source_identifier_type":"EISSN"}]},"item_1617186941041":{"attribute_name":"Source Title","attribute_value_mlt":[{"subitem_source_title":"Journal of Cardiology","subitem_source_title_language":"en"}]},"item_1617187056579":{"attribute_name":"bibliographic_information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2023-12","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"6","bibliographicPageEnd":"472","bibliographicPageStart":"467","bibliographicVolumeNumber":"82"}]},"item_1617258105262":{"attribute_name":"item_1617258105262","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_1617265215918":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_1617605131499":{"attribute_name":"File","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2024-12-01"}],"filename":"K_No82p467.pdf","filesize":[{"value":"340 KB"}],"mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://u-ryukyu.repo.nii.ac.jp/record/2020587/files/K_No82p467.pdf"},"version_id":"784d2cbc-0eeb-49b6-acca-32a2455c9994"},{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2024-12-01"}],"filename":"K_No82p467_figure1-3_Graphical abstract.pdf","filesize":[{"value":"343 KB"}],"mimetype":"application/pdf","url":{"objectType":"other","url":"https://u-ryukyu.repo.nii.ac.jp/record/2020587/files/K_No82p467_figure1-3_Graphical abstract.pdf"},"version_id":"127c05f2-93b2-4bca-ace3-0a6a966f585c"}]},"item_title":"Effectiveness of Surveillance by Echocardiography for Cancer Therapeutics-Related Cardiac Dysfunction of Patients with Breast Cancer","item_type_id":"59","owner":"8","path":["1642838338003","1642838407795"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2024-12-01"},"publish_date":"2024-12-01","publish_status":"0","recid":"2020587","relation_version_is_last":true,"title":["Effectiveness of Surveillance by Echocardiography for Cancer Therapeutics-Related Cardiac Dysfunction of Patients with Breast Cancer"],"weko_creator_id":"8","weko_shared_id":-1},"updated":"2025-02-18T11:43:11.488874+00:00"}